Lindy L. Bancke

Lindy Bancke, Pharm.D., joined Rebiotix in 2018 with a strong background in clinical development and strategic leadership at biotech and mid-size pharmaceutical companies. Dr. Bancke’s clinical and program leadership experience spans first-in-human studies to global Phase 3 trials, as well as products with orphan designation, fast track status, and unique regulatory pathway.

Prior to joining Rebiotix, Dr. Bancke spent 10 years at Upsher-Smith Laboratories, leading clinical trials and research strategy, as well as cross-functional development programs for both ANDA and NDA products. Most recently, she was the Clinical and Development Program Lead at Proximagen, a privately-held biotech company focused on small molecule drug discovery and development. Here, she was the lead for an early-phase neuro-oncology program, as well as working on a late-stage epilepsy product preparing for NDA submission.

Dr. Bancke received her undergraduate degree in biology from the University of Nebraska–Lincoln and earned a PharmD from the University of Nebraska Medical Center, after which she completed a post-doctoral fellowship in clinical research.